Evidence map›Paper›PMID 37654190›Full record

ArticleInternational journal of oncology2023

CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxia‑induced invasion and therapeutic resistance.

Jan C Lumibao, Payton L Haak, Vladimir L Kolossov, Jee-Wei Emily Chen, Jeremy Stutchman, Alejandra Ruiz, Mayandi Sivaguru, Jann N Sarkaria, Brendan A C Harley, Andrew J Steelman and 1 more

Abstract read
In one paragraph

Article in International journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  13. Article
  14. Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jan C LumibaoCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Payton L HaakCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Vladimir L KolossovCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Jee-Wei Emily ChenCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Jeremy StutchmanCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Alejandra RuizCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Mayandi SivaguruCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905,USA.
Brendan A C HarleyCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
Andrew J SteelmanCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.
H Rex GaskinsCarl R. Woese Institute for Genomic Biology, University of Illinois Urbana‑Champaign, Urbana, IL 61801, USA.

Funding

Synthetic manipulation of engineered perivascular nichesR01CA256481 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HARLEY, BRENDAN A. · 2021 to 2025
$3.4M
Biomimetic Hydrogel Niches to Study the Malignant Phenotype of Glioblastoma MultiformeR01CA197488 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HARLEY, BRENDAN A. · 2016 to 2020
$2.2M
NCI NIH HHS R01 CA197488NCI NIH HHS R01 CA256481
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and malignant primary brain tumor affecting adults and remains incurable. The mitochondrial coiled‑coil‑helix‑coiled‑coil‑helix domain‑containing protein 2 (CHCHD2) has been demonstrated to mediate mitochondrial respiration, nuclear gene expression and cell migration; however, evidence of this in GBM is lacking. In the present study, it was hypothesized that CHCHD2 may play a functional role in U87 GBM cells expressing the constitutively active epidermal growth factor receptor variant III (EGFRvIII). The amplification of the

Indexed as

Brain NeoplasmsGlioblastomaAdultCell Line, TumorCell ProliferationDNA-Binding ProteinsDrug Resistance, NeoplasmErbB ReceptorsHumansHypoxiaMitochondriaTranscription FactorsCHCHD2 protein, humanDNA-Binding ProteinsErbB ReceptorsTranscription Factorscoiled‑coil‑helix‑coiled‑ coil‑helix domain‑containing protein 2epidermal growth factor receptor variant IIIglioblastomamitochondria

Identifiers

PMID37654190
PMCPMC10546377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.